Sepsis Early Detection Remains a Clinical Guessing Game — No Rapid Point-of-Care Test Exists

Sepsis kills ~270,000 Americans annually and is the most expensive hospital condition. Current biomarkers (CRP, procalcitonin, IL-6) lack specificity and take hours to return results. There is no rapid point-of-care test that reliably detects sepsis before organ failure begins.

CRP rises in any inflammation (not specific to infection). Procalcitonin has better specificity but sensitivity of only 77% for sepsis. Blood cultures take 24-72 hours and are positive in only ~30% of sepsis cases. Biosensor-based POC platforms account for 43% of emerging diagnostic approaches, followed by chip-based platforms (25%) and molecular diagnostics (13%). An FDA-authorized AI/ML tool for sepsis prediction was published in NEJM AI, but requires EHR integration and doesn't solve the biomarker gap. Combined biomarker panels and omics-based approaches show promise but lack clinical validation at scale.

Why It Matters

Sepsis costs US hospitals $62B+/year. Each hour of delayed antibiotic treatment increases mortality 7.6%. Early detection could save 50,000+ lives/year in the US alone. A reliable POC test would transform emergency medicine.

Startup Approach

Develop a rapid (<15 min) point-of-care sepsis detection platform combining multiple biomarkers (procalcitonin, IL-6, presepsin, pancreatic stone protein) with machine learning classification. Use microfluidic lateral flow or electrochemical biosensor format for bedside use in emergency departments.

NIH Funding

NIBIB funds POC diagnostic development. NIGMS funds sepsis biology research. BARDA funds rapid diagnostic development for infectious disease.

Who's Working On It

Cytovale (IntelliSep, FDA-cleared leukocyte morphology test), Inflammatix (host-response gene expression), Beckman Coulter (procalcitonin assays), AI/ML sepsis prediction tools (Epic, Cerner integration)